The story of the erectile dysfunction drug presents a complex picture for investors. While the initial launch generated massive profits, the lapse of its patent opened the avenue to generic versions, dramatically eroding market share. This creates a unique risk for pharmaceutical companies banking on related blockbuster products, suggesting that a

The story of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, generating billions in sales , its patent expiration created a flood of knock-off medications, significantly eroding its dominance. While some firms may seek to capitalize on male sexual dysfunction, the present landscape d